Innovative approaches utilizing cellular senescence, like inducing senescence in breast cancer brain metastasis (BCBM) cells via doxorubicin, can enhance PD1-expressing T cell recruitment, improving anti-PD1 therapy efficacy [110]. This evidence concerns the gene PDCD1 and breast carcinoma.